Polaryx Therapeutics reported net income of -$1.40M for the quarter ended Jun 2026. This income statement covers 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2024 | Mar2025 | Jun2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|
| Operating items | ||||||
| Research & DevelopmentR&D | 4.72M | 0.48M | 0.68M | 0.72M | ||
| Selling, General & AdministrativeSG&A | 0.34M | 0.41M | 1.28M | 0.66M | ||
| Operating ExpensesOpex | 5.05M | 0.88M | 1.96M | 1.38M | ||
| Operating IncomeOp. Inc | -5.05M | -0.88M | -1.96M | -1.38M | ||
| EBIT | -5.05M | -0.88M | -1.96M | -1.38M | ||
| Net income details | ||||||
| EBT | -5.05M | -0.88M | -1.96M | -1.38M | ||
| Profit After TaxPAT | -5.10M | -1.01M | -2.54M | -1.40M | ||
| Income from Continuing OperationsIncome (Continuing) | -5.05M | -0.88M | -1.96M | -1.38M | ||
| Consolidated Net IncomeConsol Net Inc. | -5.05M | -0.88M | -1.96M | -1.38M | ||
| Income towards Parent CompanyParent Net Inc | -5.05M | -0.88M | -1.96M | -1.38M | ||
| Net Income towards Common StockholdersNet Income | -5.05M | -1.01M | -2.54M | -1.38M | ||
| Additional items | ||||||
| EPS (Basic) | -0.11 | -0.02 | -0.05 | -0.03 | ||
| EPS (Diluted) | -0.11 | -0.02 | -0.05 | -0.03 | ||
| Shares Outstanding | 34.20M | 44.34M | 44.67M | 45.42M | 47.22M | 48.28M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 34.20M | 44.34M | 44.67M | 45.42M | 47.22M | 48.28M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 34.20M | 45.07M | 45.07M | 47.34M | 47.34M | 49.85M |
| EBITDA | -5.05M | -0.88M | -1.96M | -1.38M |